Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population

Hepatology

Volumn 40, Issue 4, 2004, Pages 892-899

  Piasecki, Barbara A ^a,b,c,d   Lewis, James D ^a,c   Reddy, K Rajender ^a   Bellamy, Scarlett L ^a,c   Porter, Steven B ^a   Weinrieb, Robert M ^a,b   Stieritz, Donald D ^b   Chang, Kyong Mi ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C ANTIBODY; INTERFERON; VIRUS RNA;

ADULT; AFRICAN AMERICAN; AGE; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; COMORBIDITY; CONVALESCENCE; DISEASE ASSOCIATION; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RACE; RACE DIFFERENCE; SOLDIER; UNITED STATES; VIRUS SHEDDING;

EID: 4644220962     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.1840400419     Document Type: Article

References (45)

1. Alter M, Kruszon-Moran D, Nainan O, McQuillan G, Gao F, Moyer L, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562.
2. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-1233.
3. Diepolder H, Zachoval R, Hoffman R, Wierenga E, Santantonio T, Jung M, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346:1006-1007.
4. Lechner F, Wong D, Dunbar P, Chapman R, Chung R, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
5. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the antiviral cell-mediated immune response. J Clin Invest 1996;98:706-714.
6. Rehermann B, Chang KM, McHutchison J, Kokka R, Houghton M, Rice C, et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996;70:7092-7102.
7. Chang KM, Thimme R, Melpolder J, Oldach D, Pemberton J, Moorhead-Loudis J, et al. Differential CD4(+) and CD8(+) T cell responsiveness in hepatitis C virus infection. HEPATOLOGY 2001;33:267-276.
8. Thomas DL, Astemborski J, Rai R, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. J Am Med Assoc 2000;284:450-456.
9. Wright T, Donegan E, Hsu H, Ferrell L, Lake J, Kimm M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-322.
10. El-Serag H, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
11. Di Bisceglie A, Hoofnagle J. Optimal therapy of hepatitis C. HEPATOLOGY 2002;36(Suppl 1):S121-S127.
12. Mendenhall C, Moritz T, Rouster S, Roselle G, Polito A, Quan S, et al. Epidemiology of hepatitis C among veterans with alcoholic liver disease. The VA Cooperative Study Group 275. Am J Gastroenterol 1993;88:1022-1026.
13. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000;119:1385-1396.
14. Sugimoto K, Stadanlick J, Ikeda F, Brensinger C, Furth E, Alter HJ, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. HEPATOLOGY 2003;37:590-599.
15. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with Interferon in chronic hepatitis C. HEPATOLOGY 1999;30:787-793.
16. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histologic progression. Am J Gastroenterol 2002;97:700-706.
17. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, et al. The impact of Interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000;119:1317-1323.
18. Jeffers LJ, Cassidy W, Howell C, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. HEPATOLOGY 2004;36:1702-1708.
19. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. HEPATOLOGY 2003;37:1343-1350.
20. Coelho-Little M, Jeffers L, Bernstein D, Goodman J, Reddy K, deMedina M, et al. Hepatitis C virus in alcoholic patients with and without clinically apparent liver disease. Alcohol Clin Exp Res 1995;19:1173-1176.
21. Jamal M, Morgan T. Liver disease in alcohol and hepatitis C. Best Pract Res Clin Gastroenterol 2003;17:649-662.
22. Loguericio C, Pierro MD, Marino MPD, Federico A, Disalvo D, Crafa E, et al. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol 2000;35:296-301.
23. Okazaki T, Yoshihara H, Suzuki K, Yamada Y, Tsujimura T, Kawano K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Scand J Gastroenterol 1994;29:1039-1043.
24. Oshita M, Hayashi N, Kasahara A, Hagiwara H, Mita E, Naito M, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. HEPATOLOGY 1994;20:1115-1120.
25. Ohnishi K, Matsuo S, Matsutani K, Itahashi M, Kakihara K, Suzuki K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996;91:1374-1379.
26. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. HEPATOLOGY 1998;28:805-809.
27. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC M, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
28. Briggs ME, Baker C, Hall R, Gaziano JM, Gagnon D, Bzowej N, et al. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. HEPATOLOGY 2001;34:1200-1205.
29. Cheung RC. Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol 2000;95:740-747.
30. Gretch DR. Diagnostic tests for hepatitis C. HEPATOLOGY 1997;26(Suppl 1):S43-S47.
31. Ewing J. Detecting alcoholism: the CAGE questionnaire. J Am Med Assoc 1984;252:1905-1907.
32. Vogt M, Lang T, Frosner G, Klingler C, Sendl A, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:912-913.
33. El-Serag H, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002;123:476-482.
34. Lehman CL, Cheung RC. Depression, anxiety, post-traumatic stress and alcohol-related problems among veterans with chronic hepatitis C. Am J Gastroenterol 2002;97:2640-2646.
35. Liskow B, Powell B, Penick E, Nickel E, Wallace D, Landon J, et al. Mortality in male alcoholics after ten to fourteen years. J Stud Alcohol 2000;61:853-861.
36. Jerrells TR. Alcohol effects on the immune system: third annual meeting of the alcohol and drug abuse immunology symposium, Vail, Colorado, March 25-29, 1993. Alcohol 1993;10:335-342.
37. Macgregor RR, Louria DB. Alcohol and infection. Curr Clin Top Infect Dis 1997;17:291-315.
38. Roselle G, Mendenhall C, Chedid A, Moritz T, Gartside P. Alcohol modulation of immune function: clinical and experimental data. Alcohol Clin Exp Res 1995;19:551-554.
39. Encke J, Wands JR. Ethanol inhibition: the humoral and cellular immune response to hepatitis C virus NS5 protein after genetic immunization. Alcohol Clin Exp Res 2000;24:1063-1069.
40. Geissler M, Gesien A, Wands JR. Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine-expressing plasmids. J Immunol 1997;159:5107-5113.
41. Mendenhall C, Seef L, Diehl A, Shosn S, French S, Gartside P, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: Their prevalence and clinical relevance: the VA Cooperative Study Group. HEPATOLOGY 1991;14:581-589.
42. Pillot J, Poynard T, Elias A, Maillard J, Lazizi Y, Brancer M, et al. Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine. Vaccine 1995;13:289-294.
43. Zhang T, Li Y, Lai J-P, Douglas SD, Metzger DS, O'Brien CP, et al. Alcohol potentiates hepatitis C virus replicon expression. HEPATOLOGY 2003;38:57-65.
44. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. HEPATOLOGY 1999;29:908-914.
45. Szabo G. Consequences of alcohol consumption on host defence. Alcohol Alcohol 1999;34:830-841.